DaburFuture Directions
Future Science Strategy
The existing evidence base for Dabur Chyawanprash (DCP) provides a foundation for further investigation of its biological activity across immune function, oxidative stress, cellular resilience, healthy ageing, and metabolic health. Future research should focus on strengthening the translation of mechanistic findings into standardized human evidence through well-designed prospective clinical studies with defined populations, appropriate comparators, validated analytical methods, and predefined endpoints.
Given the multi-constituent nature of DCP, an integrated systems-biology approach incorporating phytochemical characterization, biomarkers, multi-omics, network pharmacology, and microbiome profiling may provide further insight into its biological mechanisms.
The overall objective should be to establish a traceable evidence continuum:
Biomarker-based trials
Future clinical studies should incorporate validated biomarkers to objectively characterize biological responses to DCP. Potential areas include immune biomarkers such as NK-cell activity, immune-cell phenotyping, cytokine profiles, and inflammatory markers; oxidative-stress markers including lipid peroxidation, protein oxidation, and antioxidant capacity; and markers relevant to cellular ageing, mitochondrial function, and metabolic health.
Biomarker findings should, where possible, be evaluated alongside physiological or clinical outcomes, as changes in mechanistic biomarkers alone do not establish clinical benefit. Longitudinal designs may further help assess persistence of response, dose-response relationships, and inter-individual variability.
NK-cell activity, immune-cell phenotyping, cytokine profiles, and inflammatory markers
Lipid peroxidation, protein oxidation, and antioxidant capacity
Markers relevant to cellular ageing, mitochondrial function, and metabolic health
Gut microbiome studies
The gut microbiome represents an emerging area for DCP research. Future studies may evaluate changes in microbial composition, diversity, functional capacity, and microbiome-derived metabolites using validated sequencing, metagenomic, and metabolomic approaches.
Integration of microbiome data with immune, inflammatory, metabolic, and metabolomic biomarkers may help characterize potential gut–host interactions and identify factors contributing to inter-individual response. Appropriate baseline characterization, longitudinal sampling, dietary assessment, and comparator groups will be important for interpretation.
NoteMicrobiome associations should be supported by functional or clinical evidence before being interpreted as biologically beneficial.
Research priorities
- 01Prospective trials with predefined endpoints
- 02Validated immune and oxidative-stress biomarkers
- 03Multi-omics and network pharmacology
- 04Longitudinal microbiome profiling